Leukaemia, Lymphocytic, Chronic Clinical Trial
Official title:
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Ofatumumab is an IgG1κ fully human monoclonal antibody (mAb) that specifically recognizes an
epitope on the human differentiation antigen CD20 molecule. In vitro and in vivo studies
demonstrated that ofatumumab depletes CD20 positive (CD20+) B cells through
complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity
(ADCC), which results in the antitumour effect.
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of
ofatumumab monotherapy in chronic lymphocytic leukemia (CLL) patients. Ofatumumab will be
administered intravenously at the first dose of 300mg followed by 7 weekly infusions of
2000mg, followed by 4 infusions of 2000mg at every 4 weeks.
Primary objective of the study (Part A) is to evaluate tolerability, and the study (Part B)
is to assess overall response rate in CLL population.
10 subjects will be enrolled into this study. Subjects will be followed for 48 weeks.
Ofatumumab is an IgG1κ fully human monoclonal antibody (mAb) that specifically recognizes an
epitope on the human differentiation antigen CD20 molecule. In vitro and in vivo studies
demonstrated that ofatumumab depletes CD20 positive (CD20+) B cells through
complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity
(ADCC), which results in the antitumour effect.
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of
ofatumumab monotherapy in chronic lymphocytic leukemia (CLL) patients. Ofatumumab will be
administered intravenously at the first dose of 300mg followed by 7 weekly infusions of
2000mg, followed by 4 infusions of 2000mg at every 4 weeks.
Primary objective of the study (Part A) is to evaluate tolerability, and the study (Part B)
is to assess overall response rate in CLL population.
10 subjects will be enrolled into this study. Subjects will be followed for 48 weeks.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01453062 -
Phase IV Observational Study in Chronic Lymphocytic Leukemia
|
N/A | |
Terminated |
NCT01039376 -
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
|
Phase 3 | |
Completed |
NCT01110031 -
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
|
Phase 1 | |
Active, not recruiting |
NCT01520922 -
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
|
Phase 2 | |
Completed |
NCT00824265 -
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
|
Phase 3 | |
Completed |
NCT00349349 -
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
|
Phase 2 | |
Completed |
NCT00802737 -
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
|
Phase 4 | |
Completed |
NCT00410163 -
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
|
Phase 2 | |
Terminated |
NCT00748189 -
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
|
Phase 3 | |
Completed |
NCT01563055 -
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
|
Phase 2 |